Company intelligence / Profile preview
Lerna Biopharma
Singapore, Singaporelernabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lerna Biopharma’s lead program (LR1) uses siRNA to promote liver regeneration and protect against further deterioration in chronic liver disease models. Preclinical data suggest potential to transform treatment for cirrhosis and reduce the need for transplantation. The company leverages its proprietary Quartz platform for target discovery and pipeline expansion but has not yet advanced programs into clinical trials as of May 2025
- Therapeutic areas
- GastroenterologyOphthalmology
- Modalities
- siRNA (small interfering RNA)oligonucleotide therapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Lerna Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lerna Biopharma.